Search Page

1

Cite

Share

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.

Adashek JJ, Jain RK, Zhang J. Adashek JJ, et al. Cells. 2019 Aug 9;8(8):860. doi: 10.3390/cells8080860. Cells. 2019. PMID: 31404966 Free PMC article. Review.

Cite

Share

2

Cite

Share

SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy.

Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. Mardinian K, et al. Among authors: adashek jj. Mol Cancer Ther. 2021 Dec;20(12):2341-2351. doi: 10.1158/1535-7163.MCT-21-0433. Epub 2021 Oct 12. Mol Cancer Ther. 2021. PMID: 34642211 Free PMC article. Review.

Cite

Share

3

Cite

Share

Missing the target in cancer therapy.

Adashek JJ, Goloubev A, Kato S, Kurzrock R. Adashek JJ, et al. Nat Cancer. 2021 Apr;2:369-371. doi: 10.1038/s43018-021-00204-w. Epub 2021 Apr 12. Nat Cancer. 2021. PMID: 34368781 Free PMC article.

Cite

Share

4

Cite

Share

If Walls Could Talk.

Adashek JJ. Adashek JJ. Oncologist. 2019 May;24(5):720. doi: 10.1634/theoncologist.2019-0111. Epub 2019 Mar 21. Oncologist. 2019. PMID: 30898890 Free PMC article.

Cite

Share

5

Cite

Share

Balancing clinical evidence in the context of a pandemic.

Adashek JJ, Kurzrock R. Adashek JJ, et al. Nat Biotechnol. 2021 Mar;39(3):270-274. doi: 10.1038/s41587-021-00834-6. Nat Biotechnol. 2021. PMID: 33547424 No abstract available.

Cite

Share

6

Cite

Share

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.

Adashek JJ, Subbiah V, Kurzrock R. Adashek JJ, et al. Trends Cancer. 2021 Jan;7(1):15-28. doi: 10.1016/j.trecan.2020.08.009. Epub 2020 Sep 29. Trends Cancer. 2021. PMID: 33008795 Free article. Review.

Cite

Share

7

Cite

Share

Adjuvant treatment in renal cell carcinoma.

Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK. Dizman N, et al. Among authors: adashek jj. Clin Adv Hematol Oncol. 2018 Aug;16(8):555-563. Clin Adv Hematol Oncol. 2018. PMID: 30148828 Review.

Cite

Share

8

Cite

Share

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?

Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, Subbiah V. Adashek JJ, et al. Trends Cancer. 2020 Mar;6(3):181-191. doi: 10.1016/j.trecan.2020.01.005. Epub 2020 Feb 6. Trends Cancer. 2020. PMID: 32101722 Free article. Review.

Cite

Share

9

Cite

Share

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.

Adashek JJ, Desai AP, Andreev-Drakhlin AY, Roszik J, Cote GJ, Subbiah V. Adashek JJ, et al. Mol Cancer Ther. 2021 Oct;20(10):1769-1776. doi: 10.1158/1535-7163.MCT-21-0329. Epub 2021 Sep 6. Mol Cancer Ther. 2021. PMID: 34493590 Free PMC article. Review.

Cite

Share

10

Cite

Share

Cancer Genetics and Therapeutic Opportunities in Urologic Practice.

Adashek JJ, Leonard A, Roszik J, Menta AK, Genovese G, Subbiah V, Msaouel P. Adashek JJ, et al. Cancers (Basel). 2020 Mar 18;12(3):710. doi: 10.3390/cancers12030710. Cancers (Basel). 2020. PMID: 32197306 Free PMC article. Review.

Cite

Share